• Rigel Pharmaceuticals named board member Alison L. Hannah as executive vice president, chief medical officer, effective July 1, 2026.
• Hannah resigned from the board in connection with the appointment; she has decades of oncology drug development experience.
• She succeeds Lisa Rojkjaer as chief medical officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607010805PR_NEWS_USPR_____SF96162) on July 01, 2026, and is solely responsible for the information contained therein.